There are about 10560 clinical studies being (or have been) conducted in Taiwan. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
Liver transplantation is the last-line method for liver failure. Thomas Starzl completed the first liver transplant in 1967, liver transplantation is developing rapidly. In Taiwan, the first liver transplantation was started in 1984, and the living donor liver transplantation was started in 1994. According to statistics from the Taiwan Organ Transplant Registration Center, from 2005 to 2018, a total of 6,211 liver transplants were completed in Taiwan, and the three-year survival rate was 78.9%. The success rate of liver transplantation is closely related to the operation method, complications, the patient's conditions, and postoperative care. Besides, Liver cancer is the sixth most common cancer in the whole world and also the fourth leading cause of cancer-related death. Approximately 90% of patients are diagnosed with liver cirrhosis at the same time when they are diagnosed with liver cancer. Once the late stages of liver cirrhosis happen, the effect of treatment will be reduced. Therefore, liver transplantation is the only treatment option that can solve the simultaneous occurrence of liver cirrhosis and liver cancer. Since 1996, liver transplantation has been used to treat liver cancer, the organ source is always the Achilles tendon of organ transplantation. Therefore, Milan criteria was designed to achieve the justice of organ share. However, living donor liver transplant is more popular in Eastern countries because of religious factors and ethical issues and many famous medical centers are trying to expand the original Milan or UCSF criteria, such as Kyoto criteria and Up-to-7 criteria, hoping to save more patients. However, with the expansion of conditions, the chance of recurrence or metastasis after transplantation is bound to increase. According to reports from different famous medical centers, the recurrence rate of liver cancer after liver transplantation is about 10-20%. Therefore, we assume that patients with liver replacement caused by different diseases may have other postoperative conditions and complications. This study will review the preoperative diagnosis, surgical status, postoperative status, medication status, complications and recurrence of liver transplant patients in our hospital for statistical analysis.
The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).
The investigator would like to investigate the impact of theta-burst stimulation over cerebellum in adults with autism spectrum disorder
Patients with liver cancer expected to undergo radiofrequency ablation or transvascular embolization. Relevant tumor markers (AFP and methylation analysis) were performed. The two data are then counted and compared.
This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-naïve adults 50 years of age and older. The polyvalent (23-valent) pneumococcal vaccine, PPSV23, is the active comparator. In addition to studying safety/tolerability, it is hypothesized that, at 30 days postvaccination, the immunogenicity of V116 is noninferior to PPSV23 for the 12 common serotypes in V116 and PPSV23, and that V116 is superior to PPSV23 for the 9 serotypes unique to V116. It is also hypothesized that V116 is superior to PPSV23 in the percentage of participants with ≥4-fold rise from baseline in unique V116 serotypes, as measured by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs).
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms. Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.
The purpose of this study is to provide continued access to treatment for participants who continue to benefit from treatment.
The purpose of this 20-week randomized double-blind study in patients with resistant hypertension (rHTN) is to evaluate the efficacy, safety, and tolerability, of different doses of XXB750 administered as subcutaneous (SC) injections, compared to placebo. Since all study participants will be patients with rHTN, all study treatments will be given on top of maximally tolerated background antihypertensive therapy recommended by international guidelines for treatment of HTN (i.e., a thiazide or a thiazide-like diuretic, an angiotensin converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB), and a long-acting dihydropyridine calcium channel blocker (CCB).
The aim of this study is to investigate the anti-exercise-fatigue effects of rice protein RP-80NY in men
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.